Corvus Pharmaceuticals, Inc.

NASDAQ:CRVS

Biotechnology

Healthcare
$10.17 -1.58%

-$0.19 today

Market cap
$857.87M
Beta
0.84
P/E (TTM)
-24.1
EPS (TTM)
-$0.49
52W Low $3.55High $26.95

Volume 0.93M

Average 1.49M

Returns on capital

Corvus Pharmaceuticals, Inc. management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

-25.0%

avg -46.6%

ROIC

-69.1%

avg -52.8%

ROA

-21.5%

avg -44.6%

Analysis

ROA is currently the strongest return metric at -21.5% versus its period average of -44.6%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Leiv Lea

Chief Financial OfficerUSD 411.95K72400.00K0.48%

William Benton Jones

Senior Vice President of Pharmaceutical DevelopmentUSD 366.12K60400.00K0.48%

Peter A. Thompson FACP

Co-Founder & Independent DirectorUSD 47K66——

Richard A. Miller

Co-Founder, President, Chief Executive Officer & Chairman of the BoardUSD 42.57K75——

Jeffrey S. Arcara

Senior Vice President & Chief Business Officer—57——

Compensation is shown in the reported currency; data updated Nov 7, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Dec 4, 2025.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

Buys

7

$384,164.25

Sells

0

$0.00

Net Transaction Value

+$384,164.25

Net buying

Most Active

Arcara Jeffrey

4 transactions

Transactions sorted by date, descending.

Open-market insider purchases and sales reported during the last 12 months
Type
Nov 13, 26

Arcara Jeffrey

Direct

Buy$5.4K
Nov 13, 26

Arcara Jeffrey

Direct

Buy$5.2K
Nov 12, 26

Arcara Jeffrey

Direct

Buy$5.5K
Nov 11, 26

Arcara Jeffrey

Direct

Buy$34.4K
Jun 11, 26

Moore David Scott

Direct

Buy$250.2K
May 18, 26

MILLER RICHARD A MD

Indirect

Buy$23.2K
May 18, 26

MILLER RICHARD A MD

Indirect

Buy$60.3K

Summary

Insiders reported 7 buys worth $384,164.25 and 0 sells worth $0.00 over the last 12 months. That adds up to net buying of $384,164.25. Arcara Jeffrey was the most active insider with 4 transactions.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A2 analysts
RevenueN/AN/AN/A
N/A3 analysts
Net IncomeN/AN/AN/A
N/A3 analysts
EBITN/AN/AN/A
N/A3 analysts

Analysis

Analysis will appear once historical growth or forward estimates are available for this company.

Competitors

Who does Corvus Pharmaceuticals, Inc. compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about CRVS's management, answered from reported figures.

Who manages CRVS?

Corvus Pharmaceuticals, Inc. (CRVS) lists 5 active executives. The top listed executive is Peter A. Thompson FACP, Co-Founder & Independent Director.

Are CRVS insiders buying or selling?

Recent insider activity shows net buying of $5.14M.